{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T01:20:20Z","timestamp":1787707220472,"version":"build-2784847793"},"reference-count":71,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.idnow.2026.105316","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T22:28:13Z","timestamp":1781994493000},"page":"105316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S","title":["Antibiotic penetration in the male urinary tract: a critical review of pharmacokinetic and pharmacodynamic evidence"],"prefix":"10.1016","volume":"56","author":[{"given":"Antoine","family":"Hamon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Jullien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Cattoir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lemaitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Lafaurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Lefort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idnow.2026.105316_bb0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1464-410X.1990.tb14864.x","article-title":"Pathogenesis of chronic bacterial prostatitis in an animal model","volume":"66","author":"Nickel","year":"1990","journal-title":"Br. J. Urol."},{"key":"10.1016\/j.idnow.2026.105316_bb0010","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.chom.2024.04.015","article-title":"Variability in cell division among anatomical sites shapes Escherichia coli antibiotic survival in a urinary tract infection mouse model","volume":"32","author":"Amoura","year":"2024","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.idnow.2026.105316_bb0015","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.4049\/jimmunol.2000587","article-title":"The immune system fails to mount a protective response to gram-positive or gram-negative bacterial prostatitis","volume":"205","author":"Lupo","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.idnow.2026.105316_bb0020","first-page":"322","article-title":"Effect of urine concentration versus tissue concentration of ampicillin and mecillinam on bacterial adherence in the rat bladder","volume":"18","author":"Frimodt-M\u00f8ller","year":"1981","journal-title":"Investig. Urol."},{"key":"10.1016\/j.idnow.2026.105316_bb0025","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0924-8579(02)00105-X","article-title":"Correlation between pharmacokinetic\/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection","volume":"19","author":"Frimodt-M\u00f8ller","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.idnow.2026.105316_bb0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000074526","article-title":"Penetration of antimicrobial agents into the prostate","volume":"49","author":"Charalabopoulos","year":"2003","journal-title":"Chemotherapy"},{"key":"10.1016\/j.idnow.2026.105316_bb0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1128\/CMR.00019-07","article-title":"Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis","volume":"21","author":"Jacobsen","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.idnow.2026.105316_bb0040","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.micinf.2004.05.023","article-title":"Host subversion by formation of intracellular bacterial communities in the urinary tract","volume":"6","author":"Anderson","year":"2004","journal-title":"Microbes Infect."},{"key":"10.1016\/j.idnow.2026.105316_bb0045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0090-4295(01)01130-X","article-title":"Dynamic interactions between host and pathogen during acute urinary tract infections","volume":"57","author":"Schilling","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.idnow.2026.105316_bb0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","article-title":"Penetration of Antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations","volume":"48","author":"Landersdorfer","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.idnow.2026.105316_bb0055","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1128\/AAC.35.10.1947","article-title":"Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning","volume":"35","author":"Nix","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0060","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jmsacl.2023.12.003","article-title":"Therapeutic drug monitoring of glycopeptide antimicrobials: an overview of liquid chromatography-tandem mass spectrometry methods","volume":"31","author":"Cafaro","year":"2024","journal-title":"J Mass Spectrom Adv Clin Lab"},{"key":"10.1016\/j.idnow.2026.105316_bb0065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/dkm476","article-title":"Tissue concentrations: do we ever learn?","volume":"61","author":"Mouton","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0070","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1128\/AAC.48.5.1441-1453.2004","article-title":"Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue","volume":"48","author":"M\u00fcller","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl. 3","key":"10.1016\/j.idnow.2026.105316_bb0075","first-page":"327","article-title":"Diffusion of cefotaxime in different tissues of the urogenital tract (author\u2019s transl)","volume":"8","author":"Schalh\u00e4user","year":"1980","journal-title":"Infection"},{"key":"10.1016\/j.idnow.2026.105316_bb0080","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/BF01716082","article-title":"Penetration of ampicillin and sulbactam into human epididymis and testis","volume":"24","author":"Klotz","year":"1996","journal-title":"Infection"},{"key":"10.1016\/j.idnow.2026.105316_bb0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/bdd.2510140207","article-title":"Ceftriaxone pharmacokinetics in elderly subjects and penetration into epididymis","volume":"14","author":"Geny","year":"1993","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.idnow.2026.105316_bb0090","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/1120009X.1990.11739013","article-title":"Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man","volume":"2","author":"Fraschini","year":"1990","journal-title":"J. Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0095","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jiac.2015.04.015","article-title":"Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics","volume":"21","author":"Kobayashi","year":"2015","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0100","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/17843286.1989.11718041","article-title":"Penetration of temocillin into prostatic tissue after intravenous dosing","volume":"44","author":"Baert","year":"1989","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.idnow.2026.105316_bb0105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1185\/03007998409109582","article-title":"Serum concentrations and penetration into prostate of mecillinam and ampicillin","volume":"9","author":"Jeppesen","year":"1984","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.idnow.2026.105316_bb0110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/antibiotics12010022","article-title":"Serum and prostatic tissue concentrations of cefazolin, ciprofloxacin and Fosfomycin after prophylactic use for transurethral resection of the prostate","volume":"12","author":"Sobels","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.idnow.2026.105316_bb0115","first-page":"1","article-title":"Concentrations of ceftriaxone in prostate adenoma tissue","volume":"30","author":"Adam","year":"1984","journal-title":"Chemotherapy"},{"key":"10.1016\/j.idnow.2026.105316_bb0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF01651355","article-title":"Cefotaxime concentrations in prostatic tissue","volume":"11","author":"Genov","year":"1983","journal-title":"Infection"},{"key":"10.1016\/j.idnow.2026.105316_bb0125","first-page":"1581","article-title":"Cefixime concentration in human prostatic tissue following 3-days of administration","volume":"37","author":"Morita","year":"1991","journal-title":"Hinyokika Kiyo"},{"key":"10.1016\/j.idnow.2026.105316_bb0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/jac\/15.1.119","article-title":"Penetration of ceftazidime into the human prostate gland following intravenous injection","volume":"15","author":"Abbas","year":"1985","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/jcph.6119","article-title":"Prostatic pharmacokinetic and pharmacodynamic analysis of ceftazidime: dosing strategy for bacterial prostatitis","volume":"65","author":"Onita","year":"2025","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.idnow.2026.105316_bb0140","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/jac\/29.4.473","article-title":"An evaluation of the penetration of cefepime into prostate tissue in patients undergoing elective prostatectomy","volume":"29","author":"Arkell","year":"1992","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0145","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijantimicag.2012.11.001","article-title":"Prostatic penetration of meropenem in humans, and dosage considerations for prostatitis based on a site-specific pharmacokinetic\/pharmacodynamic evaluation","volume":"41","author":"Nishikawa","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.idnow.2026.105316_bb0150","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijantimicag.2016.04.027","article-title":"Plasma and intraprostatic concentrations of ertapenem following preoperative single dose administration: a single-Centre prospective experience and clinical implications-the ERTAPRO study","volume":"48","author":"Dariane","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.idnow.2026.105316_bb0155","first-page":"7","article-title":"Penetration of monobactam antibiotics (aztreonam, carumonam) into human prostatic tissue","volume":"35","author":"Whitby","year":"1989","journal-title":"Chemotherapy"},{"key":"10.1016\/j.idnow.2026.105316_bb0160","article-title":"Fosfomycin: pharmacological, clinical and future perspectives","volume":"6","author":"Dijkmans","year":"2017","journal-title":"Antibiotics (Basel)."},{"key":"10.1016\/j.idnow.2026.105316_bb0165","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00476-17","article-title":"In vivo pharmacokinetics and pharmacodynamics of ZTI-01 (Fosfomycin for injection) in the neutropenic murine thigh infection model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa","volume":"61","author":"Lepak","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0170","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02560-17","article-title":"Pharmacokinetics and pharmacodynamics of fosfomycin and its activity against extended-spectrum-\u03b2-lactamase-, plasmid-mediated AmpC-, and carbapenemase-producing Escherichia coli in a murine urinary tract infection model","volume":"62","author":"Zykov","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0175","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.idnow.2026.105316_bb0180","first-page":"107","article-title":"Fosfomycin distribution in the lower urinary tract after administration of fosfomycin trometamol salt","volume":"14","author":"Scaglione","year":"1994","journal-title":"Int. J. Clin. Pharmacol. Res."},{"key":"10.1016\/j.idnow.2026.105316_bb0185","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1093\/cid\/cit704","article-title":"Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis?","volume":"58","author":"Gardiner","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.idnow.2026.105316_bb0190","article-title":"Fosfomycin pharmacokinetic profile in plasma and urine and quantitative estimation in prostate and seminal vesicles after one and two consecutive doses of oral fosfomycin trometamol in healthy male volunteers","volume":"11","author":"Di Stefano","year":"2022","journal-title":"Antibiotics (Basel)."},{"key":"10.1016\/j.idnow.2026.105316_bb0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijantimicag.2013.10.018","article-title":"In vitro and intracellular activities of fosfomycin against clinical strains of listeria monocytogenes","volume":"43","author":"Lepe","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.idnow.2026.105316_bb0200","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01395-24","article-title":"Evaluation of the safety profile and intrapulmonary pharmacokinetics of intravenous fosfomycin in healthy adults","volume":"69","author":"Boole","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0205","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1128\/AAC.01301-08","article-title":"Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis","volume":"53","author":"Cheng","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0210","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1093\/jac\/dkac304","article-title":"Trimethoprim\/sulfamethoxazole pharmacodynamics against Stenotrophomonas maltophilia in the in vitro chemostat model","volume":"77","author":"Lasko","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0215","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00003088-198005050-00001","article-title":"Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)","volume":"5","author":"Patel","year":"1980","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.idnow.2026.105316_bb0220","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/0003-4819-135-1-200107030-00012","article-title":"Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections","volume":"135","author":"Gupta","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.idnow.2026.105316_bb0225","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/j.1552-4604.1974.tb02300.x","article-title":"Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses","volume":"14","author":"Kremers","year":"1974","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.idnow.2026.105316_bb0230","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1464-410X.1976.tb02748.x","article-title":"A study of concentrations of trimethoprim-sulphamethoxazole in the human prostate gland","volume":"48","author":"Dabhoiwala","year":"1976","journal-title":"Br. J. Urol."},{"key":"10.1016\/j.idnow.2026.105316_bb0235","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1464-410X.1975.tb03970.x","article-title":"The concentration of sulphamethoxazole and trimethoprim in human prostate gland","volume":"47","author":"Oosterlinck","year":"1975","journal-title":"Br. J. Urol."},{"key":"10.1016\/j.idnow.2026.105316_bb0240","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0090-4295(76)90339-3","article-title":"Prostatic tissue and fluid concentrations of trimethoprim and sulfamethoxazole: experimental and clinical studies","volume":"8","author":"Madsen","year":"1976","journal-title":"Urology"},{"key":"10.1016\/j.idnow.2026.105316_bb0245","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1439-0272.1977.tb01285.x","article-title":"Levels of trimethoprim and sulphamethoxazole in human seminal plasma","volume":"9","author":"Eliasson","year":"1977","journal-title":"Andrologia"},{"key":"10.1016\/j.idnow.2026.105316_bb0250","first-page":"47","article-title":"The penetration of sulfadiazine, sulfamethoxazole and trimethoprim into the prostate gland, epididymis and testis in man","author":"Sepp\u00e4nen","year":"1980","journal-title":"Ann. Clin. Res."},{"key":"10.1016\/j.idnow.2026.105316_bb0255","doi-asserted-by":"crossref","first-page":"7557","DOI":"10.1128\/AAC.02995-14","article-title":"Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant mycobacterium tuberculosis","volume":"58","author":"Davies Forsman","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0260","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/jac\/48.2.185","article-title":"Effects of trimethoprim and co-trimoxazole on the morphology of listeria monocytogenes in culture medium and after phagocytosis","volume":"48","author":"Minkowski","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0265","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1442-2042.1998.tb00597.x","article-title":"Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate","volume":"5","author":"Goto","year":"1998","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.idnow.2026.105316_bb0270","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1007\/BF01661289","article-title":"Diffusion of oral ofloxacin (HOE 280) into human prostatic tissue: assessment by an improved high-performance liquid chromatographic method","volume":"14","author":"Claes","year":"1986","journal-title":"Infection"},{"issue":"Suppl. 1","key":"10.1016\/j.idnow.2026.105316_bb0275","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2165\/00003495-198700341-00011","article-title":"In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients","volume":"34","author":"Naber","year":"1987","journal-title":"Drugs"},{"key":"10.1016\/j.idnow.2026.105316_bb0280","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/BF01710740","article-title":"Penetration of ofloxacin into prostatic fluid, ejaculate and seminal fluid","volume":"21","author":"Naber","year":"1993","journal-title":"Infection"},{"key":"10.1016\/j.idnow.2026.105316_bb0285","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF02013991","article-title":"Concentrations of ciprofloxacin in serum and prostatic tissue in patients undergoing transurethral resection","volume":"5","author":"Grabe","year":"1986","journal-title":"Eur. J. Clin. Microbiol."},{"key":"10.1016\/j.idnow.2026.105316_bb0290","first-page":"13","article-title":"Ciprofloxacin distribution in prostatic tissue and fluid following oral administration","volume":"31","author":"Boerema","year":"1985","journal-title":"Chemotherapy"},{"key":"10.1016\/j.idnow.2026.105316_bb0295","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1128\/AAC.30.1.88","article-title":"Concentration of ciprofloxacin in human prostatic tissue after oral administration","volume":"30","author":"Dan","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0300","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0022-5347(17)35877-9","article-title":"Penetration of ciprofloxacin into prostatic fluid, ejaculate and seminal fluid in volunteers after an Oral dose of 750 mg","volume":"150","author":"Naber","year":"1993","journal-title":"J. Urol."},{"key":"10.1016\/j.idnow.2026.105316_bb0305","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jchromb.2016.06.051","article-title":"Ultra-high performance liquid chromatographic determination of levofloxacin in human plasma and prostate tissue with use of experimental design optimization procedures","volume":"1029\u20131030","author":"Szerkus","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.idnow.2026.105316_bb0310","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1128\/AAC.44.8.2046-2051.2000","article-title":"A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin","volume":"44","author":"Drusano","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0315","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1442-2042.2001.00276.x","article-title":"Urothelial mucosal concentration of levofloxacin administered before transurethral resection: is the mucosal concentration predictable?","volume":"8","author":"Hattori","year":"2001","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.idnow.2026.105316_bb0320","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jiac.2016.12.010","article-title":"Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue","volume":"23","author":"Sadahira","year":"2017","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0325","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1179\/joc.2006.18.5.485","article-title":"Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate","volume":"18","author":"Wagenlehner","year":"2006","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.idnow.2026.105316_bb0330","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijantimicag.2007.08.025","article-title":"Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400mg to healthy volunteers","volume":"31","author":"Wagenlehner","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.idnow.2026.105316_bb0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2019.03.001","article-title":"Optimizing dosing of nitrofurantoin from a PK\/PD point of view: what do we need to know?","volume":"43","author":"Wijma","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.idnow.2026.105316_bb0340","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.cmi.2020.03.001","article-title":"The effectiveness of nitrofurantoin, fosfomycin and trimethoprim for the treatment of cystitis in relation to renal function","volume":"26","author":"Ten Doesschate","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.idnow.2026.105316_bb0345","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1503\/cmaj.150067","article-title":"Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women","volume":"187","author":"Singh","year":"2015","journal-title":"CMAJ"},{"key":"10.1016\/j.idnow.2026.105316_bb0350","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1345\/aph.1R352","article-title":"Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL\/min: looking for the evidence","volume":"47","author":"Oplinger","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.idnow.2026.105316_bb0355","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ki.1986.211","article-title":"Benefit from high intrarenal levels of gentamicin in the treatment of E. Coli pyelonephritis","volume":"30","author":"Bergeron","year":"1986","journal-title":"Kidney Int."}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991926000734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991926000734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:44:54Z","timestamp":1787705094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991926000734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666991926000734"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2026.105316","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic penetration in the male urinary tract: a critical review of pharmacokinetic and pharmacodynamic evidence","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2026.105316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"105316"}}